Daniil Gataulin
Stock Analyst at Chardan Capital
(4.75)
# 186
Out of 5,182 analysts
134
Total ratings
60.98%
Success rate
35.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniil Gataulin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGTX Cognition Therapeutics | Maintains: Buy | $4 | $1.26 | +217.46% | 9 | Mar 27, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Buy | $35 | $9.22 | +279.61% | 8 | Mar 27, 2026 | |
| OCGN Ocugen | Maintains: Buy | $7 | $1.73 | +304.62% | 17 | Mar 25, 2026 | |
| ZURA Zura Bio | Maintains: Buy | $10 → $11 | $5.08 | +116.54% | 4 | Mar 23, 2026 | |
| ANNX Annexon | Maintains: Buy | $16 | $5.87 | +172.57% | 2 | Mar 20, 2026 | |
| CRVO CervoMed | Maintains: Buy | $15 → $21 | $3.69 | +469.11% | 9 | Mar 18, 2026 | |
| IRD Opus Genetics | Maintains: Buy | $9 → $11 | $5.11 | +115.26% | 4 | Mar 12, 2026 | |
| QURE uniQure | Maintains: Buy | $16 → $31 | $19.95 | +55.39% | 13 | Mar 9, 2026 | |
| EYPT EyePoint | Maintains: Buy | $27 → $29 | $13.20 | +119.70% | 13 | Mar 4, 2026 | |
| OTLK Outlook Therapeutics | Maintains: Neutral | $1 | $0.25 | +300.00% | 12 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 | $9.37 | +124.12% | 5 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $50 | $8.97 | +457.41% | 16 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $5.52 | +244.20% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $61 | $26.66 | +128.81% | 7 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 | $43.48 | -67.80% | 4 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 | $27.48 | +85.59% | 9 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2,200 | $4.13 | +53,168.77% | 1 | Mar 7, 2024 |
Cognition Therapeutics
Mar 27, 2026
Maintains: Buy
Price Target: $4
Current: $1.26
Upside: +217.46%
MeiraGTx Holdings
Mar 27, 2026
Maintains: Buy
Price Target: $35
Current: $9.22
Upside: +279.61%
Ocugen
Mar 25, 2026
Maintains: Buy
Price Target: $7
Current: $1.73
Upside: +304.62%
Zura Bio
Mar 23, 2026
Maintains: Buy
Price Target: $10 → $11
Current: $5.08
Upside: +116.54%
Annexon
Mar 20, 2026
Maintains: Buy
Price Target: $16
Current: $5.87
Upside: +172.57%
CervoMed
Mar 18, 2026
Maintains: Buy
Price Target: $15 → $21
Current: $3.69
Upside: +469.11%
Opus Genetics
Mar 12, 2026
Maintains: Buy
Price Target: $9 → $11
Current: $5.11
Upside: +115.26%
uniQure
Mar 9, 2026
Maintains: Buy
Price Target: $16 → $31
Current: $19.95
Upside: +55.39%
EyePoint
Mar 4, 2026
Maintains: Buy
Price Target: $27 → $29
Current: $13.20
Upside: +119.70%
Outlook Therapeutics
Feb 18, 2026
Maintains: Neutral
Price Target: $1
Current: $0.25
Upside: +300.00%
Feb 18, 2026
Maintains: Buy
Price Target: $21
Current: $9.37
Upside: +124.12%
Feb 10, 2026
Maintains: Buy
Price Target: $52 → $50
Current: $8.97
Upside: +457.41%
Dec 23, 2025
Initiates: Buy
Price Target: $19
Current: $5.52
Upside: +244.20%
Nov 17, 2025
Maintains: Buy
Price Target: $61
Current: $26.66
Upside: +128.81%
Nov 17, 2025
Maintains: Neutral
Price Target: $14
Current: $43.48
Upside: -67.80%
Nov 11, 2025
Maintains: Buy
Price Target: $51
Current: $27.48
Upside: +85.59%
Mar 7, 2024
Maintains: Buy
Price Target: $2,200
Current: $4.13
Upside: +53,168.77%